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Abstract
Background: Endoscopic approaches are gradually considered as a reliable treatment of intramucosal esophageal
squamous carcinoma. However, endoscopic resection (ER) is limited by the potential lymph node metastasis (LNM)
at various depths of mucosal and submucosal invasion.
Methods: We conducted a retrospective review of 498 patients with pT1 superficial esophageal squamous carcinoma
(SESC) who underwent surgical resection from January 2008 to August 2015. Pathological characteristics of
tumors including location, size, appearance, differentiation, invasion depth, and nodal status were reviewed, and
risk factors were analyzed.
Results: LNM was found in 0.0, 2.7, 6.3, 18.2, 15.9, and 34.3 % of the m1, m2, m3, sm1, sm2, and sm3 lesions,
respectively. Univariate logistic regression identified the presence of the tumor size > 2 cm (p < 0.05), the presence of
the poor tumor differentiation (p < 0.05), and the depth of tumor invasion (p < 0.05) and angiolymphatic invasion
(p < 0.05) to be the important risk factors associated with the prevalence of tumor-positive lymph nodes. These
findings were confirmed in multivariate logistic regression as independent predictors for LNM.
Conclusions: ER is considered as a reliable treatment of m1 to m2 lesions. Radical surgical resection (SR) is the
standard and irreplaceable therapy of sm1 to sm3 lesions. Patients with m3 lesions should undergo ER as the
initial procedure for diagnosis. And this treatment is supported only by a successful description of the tumor’s
characteristics, including (1) only muscularis mucosa invasion and without invasion of the resection margins and
(2) without any risk predictors for LNM. Otherwise, SR is recommended.
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Background
With the recent progress in endoscopic techniques, the
incidence of superficial esophageal squamous carcinoma
(SESC) is increasing. Patients with SESC may expect a
more favorable prognosis compared with those who have
advanced esophageal squamous carcinoma. The tumor
depth of these SESC is subdivided into six successive
layers (m1: intraepithelial tumors; m2: tumors invading
the lamina propria; m3: tumors invading the muscularis
mucosa; sm1: tumors invading the most superficial one
third of the submucosa; sm2: tumors invading the
middle one third of the submucosa; sm3: tumors invad-
ing deeper than the sm2 level) [1]. Due to the low preva-
lence of lymph node metastasis (LNM) of m1 and m2,
endoscopic resection (ER) is gradually considered a reli-
able treatment [2–5] with acceptable low morbidity and
mortality [6]. These excellent outcomes have promoted
some authors to consider that m3 and sm1 tumors
would be also feasible. On the other hand, others argued
that radical surgical resection (SR; the radical esophagec-
tomy with lymphadenectomy) is the standard therapy
for SESC considering the potential LNM [7, 8], although
its high risk of morbidity and mortality remain debatable
[5, 6, 9–13], not to mention the negative impact on
long-term quality of life.
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Therefore, the accurate prediction of lymph node in-
volvement in different subsets of SESC would give the
patient a favorable opportunity to receive more reason-
able treatment. The aim of this study was (1) to clarify
the relationship between clinicopathological risk factors




Consecutive patients with esophageal squamous carcin-
oma who underwent surgical resection at our hospital
between January 2008 and August 2015 were reviewed
retrospectively. A total of 498 patients with pT1 SESC
who underwent radical esophagectomy with lymphade-
nectomy were enrolled for this study. All patients were
examined with upper gastrointestinal endoscopy/endo-
scopic ultrasound with biopsy, standard chest radio-
graph, and multi-slice computed tomography (MSCT)
of the chest and upper abdomen to exclude the pres-
ence of metastatic disease, as well as an assessment of
cardiopulmonary reserve to exclude those patients with
surgical contraindication. No patients received pre-
operative neoadjuvant.
Pathological evaluation
Pathologic examination of the resected specimens was
performed at the Department of Pathology of our insti-
tution. The standard procedure for processing esopha-
gectomy specimens includes immediate assessment of
the specimen to measure tumor dimensions followed by
formalin fixation overnight. For T1 tumors with a mass
that is seen grossly, the entire mass is submitted for
histologic examination. Each resected specimen was cut
into 15 × 2 mm blocks, fixed in formalin, embedded in
paraffin, and cut into 5-μm slices. Sections were rou-
tinely stained with hematoxylin and eosin. For those
angiolymphatic invasions that were considered, immu-
nohistochemical analysis with CD31, CD34, and D2-40
was performed to seek evidence of angiolymphatic infiltra-
tions (CD31- and CD34-positive) and lymphatic invasions
(further D2-40-positive). The description of the tumor
which included tumor location, tumor size, pathologic
appearance, tumor differentiation, tumor depth, and
nodal status was pathologically evaluated. Additionally,
the subdivided depth of tumor invasion was classified
into six levels: m1 to m3 and sm1 to sm3, as described
above [1]. Tumor differentiation was classified into five
groups including I (well differentiated), I–II, II (moder-
ately differentiated), II–III, and III (poorly differenti-
ated). Tumor differentiation and/or growth pattern may
be categorized as absent variables in those patients with
very early stage tumor like high-grade dysplasia/carcin-
oma in situ. Other variables including multicentric
invasive lesions and angiolymphatic invasion were also
examined in order to find out the relationship with
LNM. Tumors classified as undifferentiated (IV), basa-
loid squamous cell carcinoma, glanular cell, or spindle
cell were excluded from this study. The pathologic
tumor stage was presented according to the 7th edition
of the American Joint Committee on Cancer TNM
classification [14].
Statistical analysis
All enrolled patients were divided into two groups ac-
cording to their results of LNM (group I with negative
LNM and group II with positive LNM). Variables sub-
jected to statistical analysis were evaluated, including
age, gender, tumor location, tumor size, pathologic
appearance, tumor differentiation, tumor depth (m1 to
m3 and sm1 to sm3), multicentric invasion, and angio-
lymphatic invasion. A χ2 test was used to compare cat-
egorical variables. The Student t test and analysis of
variance were used for comparison of continuous vari-
ables. Univariate logistic regression and multivariate
logistic regression analysis were used to identify the risk
factors and independent predictors of LNM, respectively.
All p values were two-sided, and the significance level was
set at p < 0.05. Continuous data were presented as mean ±
SD. All calculations were performed using the STATA
10.0 software (StataCorp, College Station, TX, USA).
Results
Patient demographics and clinicopathologic
characteristics
A total of 498 patients with pT1 SESC were enrolled for
this study. Table 1 shows the patients’ demographics and
clinical characteristics. Mean patient age was 60.74 years
(range from 36 to 80). The tumor originated at the cer-
vical esophagus in 16 patients, upper thoracic esophagus
in 90, middle thoracic esophagus in 248, and lower thor-
acic esophagus in 144. Tumor with erosion type was
found in 99 patients, ulcerative type in 123, fungating
type in 84, other types in 66, and with unavailable patho-
logic appearance in 126 patients. The tumor differenti-
ation included I (24 patients), I–II (71 patients), II (185
patients), II–III (86 patients), III (46 patients), and un-
available (86 patients). Eleven patients (2.2 %) were
found with tumor multicentric invasion. And there were
31 patients (6.2 %) with tumor angiolymphatic invasion.
All patients were proved to be SESC pathologically.
Among them, as shown in Table 2, 411 patients with
negative LNM were in group I and 87 with positive
LNM in group II. The characteristics in these two
groups were compared in terms of age, gender, tumor
location, tumor size, pathologic appearance, tumor dif-
ferentiation, tumor depth (m1 to sm3), multicentric
invasion, and angiolymphatic invasion. Group II had a
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significantly larger tumor size than that in group I
(2.31 ± 1.09 vs 1.73 ± 0.97, p < 0.05). There were re-
markable statistic differences (χ2 test, p < 0.05) in tumor
differentiation (I, I–II, II, II–III, III) and in angiolym-
phatic invasion (absent, present) between two groups.
The lymph node involvement in group II increased
significantly (p < 0.05) from m1 to sm3 (Table 2).
Table 1 Patient demographics and clinical characteristics
Variables Value (%)
Number 498




Upper thoracic 90 (18.1)
Middle thoracic 248 (49.8)
Lower thoracic 144 (28.9)
Tumor size (cm)
Mean ± SD (range) 1.83 ± 1.02 (0.1–6.5)
Pathologic appearance (%)
Erosive type 99 (19.9)
Ulcerative type 123 (24.7)
Fungating type 84 (16.9)























Table 2 Demographics of patients in the negative LNM and
positive LNM groups







Mean ± SD 60.91 ± 7.19 59.91 ± 7.26 0.237
Gender
Male 301 66 0.613
Female 110 21
Tumor location
Cervical 15 1 0.147
Upper thoracic 71 19
Middle thoracic 212 36
Lower thoracic 113 31
Tumor size (cm)
Mean ± SD 1.73 ± 0.97 2.31 ± 1.09 <0.05*
Pathologic appearancea
Erosive type 85 14 0.175
Ulcerative type 98 25
Fungating type 61 23
Other types 53 13
Differentiationb






m1 43 0 <0.05*
m1 to m2 vs m3
to sm3: p < 0.05
m1 to m3 vs sm1
to sm3: p < 0.05
m1 to m2 vs m3
to sm1 vs sm2 to







Absent 404 83 0.095
Present 7 4
Angiolymphatic invasion




aData available in 372 patients
bData available in 412 patients
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Pathological features based on invasion depth
LNM was found in none of the 43 patients with m1
lesions, 1 of the 37 patients (2.7 %) with m2 lesions, 5 of
the 80 patients (6.3 %) with m3 lesions, 16 of the 88 pa-
tients (18.2 %) with sm1 lesions, 18 of the 113 patients
(15.9 %) with sm2 lesions, and 47 of the 137 patients
(34.3 %) with sm3 lesions. Lymph node involvement
increased significantly (p < 0.05) from m1 to sm3, includ-
ing m1 to m2 vs m3 to sm3 (p < 0.05), m1 to m3 vs sm1
to sm3 (p < 0.05), and m1 to m2 vs m3 to sm1 vs sm2 to
sm3 (p < 0.05) (Table 2). Table 3 summarizes the number
and region of involved lymph nodes in relation to the
invasion depth in SESC. We divided the region of LNM
into four parts including the cervical region, upper thor-
acic region, middle and lower thoracic region, and ab-
dominal region. In cases with LNM, we observed that
the number and region of involved nodes increased in
correlation with the depth of invasion.
Relationships between pathological findings and LNM
Univariate analysis showed that the tumor size was
more than 2 cm (p < 0.05); the poor tumor differenti-
ation (I + I–II vs II + II–III + III, p < 0.05), the depth of
tumor invasion (m1 to m3 vs sm1 to sm3, p < 0.05),
and angiolymphatic invasion (p < 0.05) were the import-
ant risk factors associated with the prevalence of
tumor-positive lymph nodes (Table 4). And these re-
sults were also found in multivariate analysis which
meant the tumor size was more than 2 cm (p = 0.003);
the poor tumor differentiation (I + I–II vs II + II–III +
III, p = 0.004), the depth of tumor invasion (m1 to m3
vs sm1 to sm3, p = 0.005), and angiolymphatic invasion
(absent vs present, p < 0.05) were four independent pre-
dictors for LNM (Table 5). But other pathological char-
acteristics, including age (p = 0.494), gender (p = 0.613),
tumor location (p = 0.669), and multicentric invasion
(p = 0.109), were not associated with LNM as indicated
by the results of univariate logistic regression analysis
which is not mentioned in Table 5. In brief, patients
presenting as LNM-positive have larger, more poorly
differentiated, and deeper invaded tumors with higher
angiolymphatic invasion.
Discussion
SESC is defined as a tumor invading the mucosa and
submucosa. It was difficult for patients with SESC to get
early diagnosis and treatment in the past because of lack
of any subjective symptoms. From the 1980s to the
2000s, due to the progress in flexible endoscopic proced-
ure and biopsy [15], the incidence of SESC increased
from 10 % to approximately 25 %. Recently, a number ofTable 3 Number and region of involved lymph nodes in relation
to the cancerous depth in SESC of the thoracic esophagus treated
by thoracotomy
m1 m2 m3 sm1 sm2 sm3
Total number 43 37 80 88 113 137
Number of positive LN (%)
≤2 0 1 (2.7) 4 (5) 14 (15.91) 15 (13.27) 29 (21.17)
3–6 0 0 1 (1.25) 2 (2.27) 3 (2.65) 16 (11.68)
≥7 0 0 0 0 0 2 (1.46)
Number of patients regarding
regions of positive LN (%)
One region 0 1 (2.7) 4 (5) 15 (17.05) 12 (10.62) 32 (23.36)
Two regions 0 0 1 (1.25) 1 (1.14) 6 (5.31) 15 (10.95)
Three regions 0 0 0 0 0 0
Table 4 Univariate analysis of the risk factors for lymph node
metastases
Variables OR (95 % CI) p value
Gender
Male vs female 0.87 (0.51–1.49) 0.613
Age
≤60 vs >60 0.85 (0.54–1.35) 0.494
Tumor location
Cervical/upper vs middle/lower 0.89 (0.51–1.54) 0.669
Tumor size
≤2 vs >2 cm 2.56 (1.59–4.13) <0.05*
Differentiation
I + I–II vs II + II–III + III 2.85 (1.73–4.71) <0.05*
Depth of invasion
m1 to m3 vs sm1 to sm3 8.09 (3.45–18.98) <0.05*
Multicentric invasion
Absent vs present 2.78 (0.80–9.72) 0.109
Angiolymphatic invasion
Absent vs present 5.95 (2.81–12.57) <0.05*
CI confidence interval, OR odds ratio
*Statistically significant
Table 5 Multivariate analysis of histopathological predictors of
lymph node metastases
Variables OR (95 % CI) p value
Tumor size
≤2 vs >2 cm 2.22 (1.31–3.78) 0.003*
Differentiation
I + I–II vs II + II–III + III 3.73 (1.54–9.06) 0.004*
Depth of invasion
m1 to m3 vs sm1 to sm3 3.99 (1.53–10.40) 0.005*
Angiolymphatic invasion
Absent vs present 4.64 (2.05–10.52) <0.05*
CI confidence interval, OR odds ratio
*Statistically significant
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studies reported that the prevalence of SESC ranged
from to 16.9 to 34 % [3, 16–21].
Compared with advanced esophageal squamous can-
cer, the incidence of LNM in SESC is much lower. Since
the lymph node status is the strongest prognosticator of
survival of patients suffering from esophageal cancer
[22–24], the SESC without LNM is potentially curable.
Recent publications showed a lower incidence of LNM
(0–5.6 %) in the m1 to m2 layer [18, 25, 26]. On the
other hand, incidence of LNM in the sm2 to sm3 layer
ranged from 18 to 67 % [26–28]. In our study, the inci-
dence of LNM was 0.0 % of patients with m1 lesions,
2.7 % of patients with m2 lesions, 15.9 % of patients with
sm2 lesions, and 34.3 % of patients with sm3 lesions.
We also found that the number of involved lymph nodes
was significantly different between the m1 to m2 groups
and sm2 to sm3 groups. Furthermore, the involved
lymph nodes were seen in more regions of sm2 to sm3
cancer cases than those of m1 to m2. Considering the
low prevalence of LNM of m1 to m2, it is rational not to
require surgery for a cure because the morbidity and
mortality rates of SR often exceed such a low ratio of
LNM. Thus, ER is gradually considered as a reliable
treatment for m1 to m2 with curative intent [12, 18, 25,
29, 30]. Compared with traditional biopsy and conven-
tional imaging techniques (i.e., endoscopic ultrasonog-
raphy or CT), it even seems that ER can improve the
tumor staging based on the assessment of the samples
obtained. However, ER must be appropriately used with
curative intent without compromise for distant metasta-
sis or high risk of lymphatic spread.
On the other hand, due to the high ratio of LNM, SR
is obviously applicable to patients with the tumor depth
of sm2 to sm3. According to the number and the
regions of LNM in sm2 to sm3, two-phase (Ivor Lewis)
or even three-phase transthoracic esophagectomy is
chosen for a more extensive lymphadenectomy. This
extensive lymphadenectomy could decrease or even
clear the residual positive node lymphaticus at the ex-
pense of mortality, morbidity, and poor quality of life
after surgery. Tachibana and associates [23] reported
that the postoperative hospital mortality rate was ap-
proximately 5 % and the morbidity rate was 40 %.
Stephen and coauthors [31] reviewed 310 patients in 12
national cancer institutions and reported that actual
mortality rate was approximately 4.2 % and the compli-
cations of care rate were 57 %. The morbidities, such as
anastomotic leak, recurrent laryngeal nerve paralysis,
and pulmonary complications, still deteriorate the
prognosis after esophagectomy.
Furthermore, our study focused on the LNM in the
depth of m3 to sm1 tumors. The incidence of LNM in
m3 and sm1 was 6.3 and 18.2 %, respectively. Between
m1 to m2 and sm2 to sm3, the nodal metastasis
proportion of patients with m3 to sm1 lesions cannot be
neglected. Due to the limitation of ER for lymph node
biopsy, we tried to find out any predictors for LNM in
this subset of patients to prevent them from the pres-
ence of tumor cells after ER.
Based on the results of our study, patients with posi-
tive lymph nodes showed a statistically larger tumor
size, poorer differentiation, and deeper tumor invasion
than those with negative lymph nodes. These patho-
logical variables were confirmed to be associated with
LNM on both univariate and multivariate logistic re-
gression analyses. Additionally, the positive pathological
characteristics, including the maximum tumor size
more than 2 cm, poor tumor differentiation (II + II–III
+ III), and tumor with angiolymphatic invasion, were
found to be the independent predictive factors for
LNM. These findings corresponded well with some
earlier reports [21, 26, 32].
It is still controversial which treatment is suitable for
patients with m3 to sm1 tumor invasion. In this study,
we found that the proportion of number and regions
of lymph node involvement in SESC patients increased
from m1 to sm3. Univariate analyses identified that
the tumor invasion depth of submucosa (sm1 to sm3)
is a risk factor for LNM (p < 0.001). And on multivari-
ate analysis, compared with mucosal infiltration, the
presence of submucosal infiltration was presented to
be an independent prognostic factor for nodal metas-
tases (p = 0.005). These data are in line with several
studies reported before [18, 25, 30, 32]. Therefore, we
confirmed that ER is not a suitable treatment for pa-
tients with sm1 lesions. We also found some differ-
ences between sm1, sm2, and sm3. Compared with
sm2 to sm3 lesions, tumors of sm1 lesions presented
lower incidence of metastases. And the number and
regions of positive lymph nodes also increased from
sm1 to sm2 to sm3. Thus, the extent of lymphadenec-
tomy remains controversial. Furthermore, due to the
relatively low incidence of LNM, we recommend ER as
a curative treatment for patients with m3 carcinoma
who have no angiolymphatic invasion, with well tumor
differentiation (I + I–II), and tumor < 2 cm in size.
Last but not the least, it is very important whether a
true assessment of the depth of m3 invasion can be ob-
tained from ER accurately. In fact, the exact preoperative
differentiation between m3 and sm1 lesions is difficult
due to limitations of ER, such as the piecemeal resec-
tion, incomplete thickness of the submucosa damaged
by injection and cutting, and sample shrinking due to
electrocution damage or the muscularis mucosae wrin-
kle. Besides, a technically well-performed resection and
an accurate description of the invasion relative to the
deep and lateral resection margins both perform import-
ant roles in the final report. Considering these
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aforementioned situations, if there is any hesitation in
the final report of m3 invasion, SR should be recom-
mended as a remedial treatment.
Conclusions
For patients with SESC, EUS T staging and chest MSCT
are highly recommended as preoperative routines (PET-
CT is optional) to evaluate any metastasis. When node
metastasis to mediastinum can be ruled out, we propose
that ER be considered as a reliable treatment for m1 to
m2 lesions and SR be the standard and irreplaceable
therapy for sm2 to sm3 lesions. However, due to the
relatively high prevalence of lymph node for sm1 tu-
mors, we must be aware of the fact that ER for even
superficial submucosal tumors should be considered
with caution. Therefore, we recommend that patients
with sm1 tumors should undergo esophagectomy with
radical lymphadenectomy as the only effective treatment.
As we have to aim at decreasing the operative trauma,
morbidity, and mortality without compromising the
presence of potential tumor cells, the treatment strategy
for m3 lesions still remains controversial. We recom-
mend ER as the initial procedure for diagnosis. Then, a
successful pathologic report is needed to support this
treatment. This successful pathologic report includes not
only the accurate description of the tumor’s invasion
depth (only muscularis mucosa invasion) but also the
absence of any risk predictors for LNM as well as the
unambiguous description of the tumor’s deep and lateral
resection margins (without any invasion of the resection
margins). Otherwise, SR is recommended for those m3
lesions with any hesitation on the reports of tumor de-
scription by both gastroenterologists and pathologists.
Last, SR is recommended for sm1 lesions confirmed by
EUS and for those with positive mediastinum lymph
nodes indicated by MSCT or PET-CT.
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